>> how much we can trust it given that I understand this was a single-arm trial.
Generally speaking, efficacy result from early single arm trial is much more likely to be reproduced in larger ph3 trials in antibiotic/antiviral space than in oncology space.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.